American Society of Hematology

Policy News

Policy News
Subscribe to RSS
  • ASH Issues Recommendations to the NCI on CCDI Aug 23, 2019

    ASH submitted comments to the National Cancer Institute (NCI) on ways in which improved childhood cancer data sharing could inform hematology-related pediatric research questions, data collection and data analysis tools.

  • CAR T-cell Therapy: An Update on Coverage and Reimbursement Aug 14, 2019

    ASH continues to advocate for adequate coverage and reimbursement for chimeric antigen receptor T-cell (CAR-T) therapy. In early August, the Centers for Medicare and Medicaid Services (CMS) finalized policies impacting both reimbursement of and coverage for CAR-T therapy. The final Inpatient Prospective Payment System (IPPS) rule, published on August 2, and the final Decision Memo for CAR T-cell Therapy for Cancers, issued August 7.

  • Access to Care and Drug Pricing: An Update for 2019 Mar 22, 2019

    Two big healthcare issues stand out as priorities for the 116th Congress; access to care and the cost of prescription drugs.

  • Court Rules ACA Unconstitutional Dec 17, 2018

    On December 14, 2018, a federal judge in Texas ruled that the Affordable Care Act (ACA) is unconstitutional now that Congress has eliminated the individual mandate penalty. There is no immediate impact on patients, providers or insurers, but if the decision, which may be appealed to the Supreme Court, is upheld, 20 million Americans could lose coverage and the protections for individuals with pre-existing conditions could be at risk.

  • 2018 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait Dec 11, 2018

    ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.

  • 2018 ASH Advocacy Activities Dec 11, 2018

    ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.

  • 2018 ASH Advocacy Efforts to Ensure Patient Access to Care Dec 11, 2018

    In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.

  • 2018 Physician Payment Advocacy Highlights Dec 11, 2018

    In 2018, ASH commented on numerous rules and regulations proposed by the Centers for Medicare and Medicaid Services (CMS), which impact physician payment. ASH is actively involved in various advisory committees and also continues to engage with lawmakers on Capitol Hill.

  • 2018 Research and Public Health Funding Advocacy Highlights Dec 11, 2018

    During 2018, ASH continued to be highly visible in our advocacy for federal support of biomedical research and public health funding, including funding for the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC). 

  • Access to Care & Drug Pricing: 2018 Nov 20, 2018

    2018 was full of federal policies and proposals related to access to care and drug pricing. The Administration made more changes to the Affordable Care Act and highlighted that drug pricing is a priority.  


1 of 36
back to top